SPRY earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Hold, P/E -3.01. Updated 2026-07-23.
ARS Pharmaceuticals (SPRY) Research Hub
ARS Pharmaceuticals (SPRY) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.76 USD (-8.99%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.01, market cap 0.60B. This hub links to the full technical, earnings and options research available for SPRY.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.76 USD (-8.99%) |
| 52-week range | 4.73 USD – 10.87 USD |
| Trend regime | Range |
| 14-day RSI | 28.8 (Oversold) |
| Trailing P/E | -3.01 |
| Market cap | 0.60B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for SPRY
Covered Call on SPRY: how it works, illustrative setup around the real 4.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SPRY: how it works, illustrative setup around the real 4.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SPRY: how it works, illustrative setup around the real 4.76 USD price, max profit/loss, breakeven and when to use it. Educational.
SPRY technical analysis: range, last 4.76 USD, RSI 28.8, 52w range 4.73 USD–10.87 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SPRY in?
ARS Pharmaceuticals (SPRY) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SPRY in an uptrend or downtrend?
As of 2026-09-11, SPRY is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SPRY's trailing P/E ratio?
SPRY's trailing P/E is -3.01, with a market cap of 0.60B. See the earnings research page for full valuation detail.
When does SPRY next report earnings?
SPRY is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.47655 USD.